22 May 2013
Keywords: gsk, start, trials, first, hiv, vaccine, candidate
Article | 04 February 2002
GlaxoSmithKline Biologicals has initiated the first trial in humans ofits recombinant, adjuvanted candidate HIV vaccine, consisting of NefTat
and gp120 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
4 February 2002
21 May 2013
© 2013 thepharmaletter.com